NCT01392560View on ClinicalTrials.gov

Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

BI 10773

Oral once daily

Trial Locations (1)

Unknown

1245.46.10001 Boehringer Ingelheim Investigational Site, Toronto

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY